New triple therapy takes on untreatable liver cancer
NCT ID NCT06882876
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-phase trial is testing a combination of an experimental drug (JS014), an immunotherapy (toripalimab), and a targeted chemotherapy procedure (TACE) in 20 people with advanced liver cancer that cannot be surgically removed. The main goal is to check safety, but researchers will also measure how well the tumors shrink and how long patients live. Because it's a small, early study, results are not yet conclusive.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- JS014 (an experimental drug) combined with toripalimab (an immunotherapy) and transarterial chemoembolization (a procedure that blocks blood flow to the tumor and delivers chemotherapy directly)
- What this could lead to
- If this works, it could point toward a more effective treatment for people with advanced liver cancer that cannot be removed by surgery.
- What could go wrong
- This is a very early, small trial with only 20 participants. The main goal is safety, not yet proof of effectiveness. Side effects from the drug combination or the procedure could be serious.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Xiangya Hospital
Changsha, Hunan, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a 'No-Touch' microwave technique match surgery for liver tumors?
- Can blood tests reveal how liver and bile duct cancers respond to treatment?
- AI-Powered surveillance may outsmart liver cancer recurrence
- Blood markers may forecast liver cancer treatment success
- Can a diabetes drug help fight liver cancer? a trial puts it to the test
- Can a triple therapy shrink untreatable liver tumors?